A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children
NCT04070326
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class
Conditions
Hereditary Angioedema
Interventions
DRUG:
Lanadelumab
Sponsor
Shire